Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats

K. C. Huang; Yih-Giun Cherng; L. J. Chen; C. T. Hsu; J. T. Cheng

doi:10.1055/s-0033-1357161

Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats

K. C. Huang, Yih-Giun Cherng, L. J. Chen, C. T. Hsu, J. T. Cheng

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

Original language	English
Pages (from-to)	240-244
Number of pages	5
Journal	Hormone and Metabolic Research
Volume	46
Issue number	4
DOIs	https://doi.org/10.1055/s-0033-1357161
Publication status	Published - 2014

Keywords

diabetic nephropathy
FGFR
klotho
PPARγ
STZ rat
TZD

ASJC Scopus subject areas

Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical
Endocrinology, Diabetes and Metabolism
Medicine(all)

Access to Document

10.1055/s-0033-1357161

Fingerprint Dive into the research topics of 'Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats'. Together they form a unique fingerprint.

Cite this

Huang, K. C., Cherng, Y-G., Chen, L. J., Hsu, C. T., & Cheng, J. T. (2014). Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. Hormone and Metabolic Research, 46(4), 240-244. https://doi.org/10.1055/s-0033-1357161

@article{a8be30047d1541808915c2728921fa70,

title = "Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats",

abstract = "A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.",

keywords = "diabetic nephropathy, FGFR, klotho, PPARγ, STZ rat, TZD",

author = "Huang, {K. C.} and Yih-Giun Cherng and Chen, {L. J.} and Hsu, {C. T.} and Cheng, {J. T.}",

year = "2014",

doi = "10.1055/s-0033-1357161",

language = "English",

volume = "46",

pages = "240--244",

journal = "Hormone and Metabolic Research",

issn = "0018-5043",

publisher = "Georg Thieme Verlag",

number = "4",

}

TY - JOUR

T1 - Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats

AU - Huang, K. C.

AU - Cherng, Yih-Giun

AU - Chen, L. J.

AU - Hsu, C. T.

AU - Cheng, J. T.

PY - 2014

Y1 - 2014

N2 - A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

AB - A marked decrease of klotho expression was observed in the kidney of streptozotocin-induced diabetic rats (STZ rats) showing diabetic nephropathy. It has been documented that klotho is the target gene of PPARγ. However, the effect of PPARγ agonist on klotho expression in kidney of STZ rats remains obscure. Thus, we used rosiglitazone (TZD) as PPARγ agonist to investigate the effect on renal dysfunction in STZ rats. Treatment of TZD reversed the lower levels of PPARγ, klotho, and FGFR1 expressions in kidneys of STZ rats without the correction of hyperglycemia. Also, renal functions and structural defeats were improved by TZD treatment. Taken together, oral administration of TZD may improve STZ-induced diabetic nephropathy due to restoration of the expression of klotho axis through an increase in PPARγ expression without changing blood glucose in rats.

KW - diabetic nephropathy

KW - FGFR

KW - klotho

KW - PPARγ

KW - STZ rat

KW - TZD

UR - http://www.scopus.com/inward/record.url?scp=84899480561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899480561&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1357161

DO - 10.1055/s-0033-1357161

M3 - Article

C2 - 24136780

AN - SCOPUS:84899480561

VL - 46

SP - 240

EP - 244

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 4

ER -